Bellicum Pharmaceuticals
2004
FOUNDED
PUBLIC
STATUS
101-200
EMPLOYEES
BLCM
STOCK SYMBOL
$2.29
SHARE PRICE
(As of Friday Closing)
Description
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (BPX-501) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and T cell receptors (BPX-701) to treat blood cancers and solid tumors.
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 2130 West Holcombe Boulevard
- Suite 800
- Houston, TX 77030
- United States
+1 (832) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Bellicum Pharmaceuticals’s full profile, request a free trial.
Bellicum Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.72 - $4.14 | $114M | $2.10 | -$2.45 | 1.16M | 49.9M |
Bellicum Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 35,724 | 49,616 | 197,522 | 284,104 |
| Revenue | 2,322 | 1,120 | 185 | 388 |
| EBITDA | (99,623) | (88,778) | (85,598) | (66,084) |
| Net Income | (110,716) | (98,036) | (91,779) | (69,241) |
| Total Assets | 133,932 | 121,501 | 135,528 | 132,037 |
| Total Debt | 44,523 | 35,963 | 35,108 | 20,385 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bellicum Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Bellicum Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookBellicum Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Bellicum Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookBellicum Pharmaceuticals Competitors (24)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cell Medica | Venture Capital-Backed | London, United Kingdom | 00 | 00000 | 0000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 00000000000 | 00000 |
| 000000 | Venture Capital-Backed | Utrecht, Netherlands | 00.000 | 00000000000 | 00.000 | |
| 00000000 | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
Bellicum Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Bellicum Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookBellicum Pharmaceuticals Executive Team (16)
8 Former Executives
You’re viewing 5 of 16 executives. Get the full list »Bellicum Pharmaceuticals Board Members (11)
4 Former Board Members
You’re viewing 5 of 11 board members. Get the full list »